Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma

Study (n=251) found those with IDH-mutant high-risk low grade glioma, regardless of codeletion status, had an improved progression free survival when procarbazine, lomustine and vincristine was given additional to radiation therapy (HR for progression or death 0.32, p=0.003).

SPS commentary:

In contrast no significant benefit was observed with the addition of procarbazine, lomustine and vincristine in the IDH-wild-type subgroup.

Journal of Clinical Oncology